Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma

Trial Identifier: D5180C00009
Sponsor: AstraZeneca
Collaborator:
Amgen
NCTID:: NCT03406078
Start Date: March 2018
Primary Completion Date: September 2020
Study Completion Date: September 2020
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
Korean Translation
Polish Translation
Russian Translation
Spanish Translation
Spanish Translation
Turkish Translation
Ukrainian Translation

Trial Locations